NYSEARCA:IHE iShares U.S. Pharmaceuticals ETF (IHE) Price, Holdings, & News $100.95 -0.17 (-0.17%) As of 03:18 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartDividendHoldingsNews and TrendsOwnershipRatingsShort Interest About iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get IHE alerts:Sign Up Key Stats Today's Range$100.79▼$101.8850-Day Range$97.36▼$108.1652-Week Range$73.42▼$108.66Volume179,383 shsAverage Volume166,663 shsMarket Capitalization$1.56 billionAssets Under Management$1.54 billionDividend Yield1.42%Net Expense Ratio0.38%Aggregate RatingModerate Buy ETF Overview iShares U.S. Pharmaceuticals ETF, formerly iShares Dow Jones U.S. Pharmaceuticals Index Fund (the Fund), is an exchange traded fund. The Fund seeks investment results that correspond generally to the price and yield performance of the Dow Jones U.S. Select Pharmaceuticals Index (the Index). The Index measures the performance of the pharmaceuticals sector of the United States equity market, and includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines, but excludes producers of vitamins. The Fund invests in a representative sample of securities included in the Index that collectively has an investment profile similar to the Index. Due to the use of representative sampling, the Fund may or may not hold all of the securities that are included in the Index. The Fund's investment advisor is BlackRock Fund Advisors. Read More iShares U.S. Pharmaceuticals ETF ExpensesTypeIHEHealth Care ETFsEquity ETFsNYSEARCA ETFsAll ETFsManagement Fee0.38%0.55%0.57%0.50%0.53%Other Expenses0.00%0.52%0.53%0.60%0.54%Total Expense0.38%0.76%0.75%0.75%0.73%Fee Waiver0.00%-0.85%-0.67%-0.78%-0.68%Net Expense0.38%0.58%0.63%0.57%0.60% Receive IHE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for iShares U.S. Pharmaceuticals ETF and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IHE ETF News HeadlinesWhich Pharmaceuticals ETF Is the Better Buy: iShares’ IHE or Invesco’s PJP?October 11, 2026 | fool.comBetter Pharma ETF: iShares IHE vs. State Street XPHOctober 10, 2026 | fool.comINSANE DRONE FOOTAGENew drone footage shows a mysterious factory rising at one of Elon Musk's most secure facilities, cleared and built in a matter of weeks. James Altucher says the site could go live as soon as October 21 and has put together a free presentation explaining what is happening inside and why the timing matters.October 16 at 1:00 AM | Paradigm Press (Ad)IHE: Innovation Supports The Outlook, Valuation Limits ConvictionSeptember 11, 2026 | seekingalpha.comIHE: Large-Cap Pharma Cools After A Hot SummerSeptember 10, 2026 | seekingalpha.com(IHE) iShares U.S. Pharmaceuticals ETFSeptember 9, 2026 | sa.investing.comSee More Headlines IHE ETF - Frequently Asked Questions How have IHE shares performed this year? iShares U.S. Pharmaceuticals ETF's stock was trading at $84.83 on January 1st, 2026. Since then, IHE shares have increased by 19.5% and is now trading at $101.3640. When did iShares U.S. Pharmaceuticals ETF's stock split? iShares U.S. Pharmaceuticals ETF's stock split on Thursday, March 7th 2024.The 3-1 split was announced on Thursday, March 7th 2024. The newly created shares were payable to shareholders after the closing bell on Thursday, March 7th 2024. An investor that had 100 shares of stock prior to the split would have 300 shares after the split. Who are iShares U.S. Pharmaceuticals ETF's major shareholders? Top institutional shareholders of iShares U.S. Pharmaceuticals ETF include MinichMacGregor Wealth Management LLC (2.06%), Congress Asset Management Co. (0.34%), AdvisorNet Financial Inc (0.34%) and Cadent Capital Advisors LLC (0.22%). How do I buy shares of iShares U.S. Pharmaceuticals ETF? Shares of IHE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of iShares U.S. Pharmaceuticals ETF own? Based on aggregate information from My MarketBeat watchlists, some other companies that iShares U.S. Pharmaceuticals ETF investors own include NVIDIA (NVDA), Broadcom (AVGO), Micron Technology (MU), JPMorgan Chase & Co. (JPM), CocaCola (KO), Eli Lilly and Company (LLY) and Visa (V). Fund Details IssueriShares Fund NameiShares U.S. Pharmaceuticals ETF Tax ClassificationRegulated Investment Company Stock ExchangeNYSEARCACurrent SymbolNYSEARCA:IHE Inception Date5/1/2006 Fund ManagerDiane Hsiung, Jennifer Hsui, Greg Savage, Alan Mason Webwww.iShares.com PhoneN/AFund Focus Asset ClassEquity BenchmarkDow Jones U.S. Select Pharmaceuticals Index CategorySector FocusHealth Care Development LevelDeveloped Markets RegionNorth America Number of Holdings57 Fund Statistics Assets Under Management$1.54 billion Average Daily Volume$245.45 thousand Discount/Premium-0.02% Administrator, Advisor and Custodian AdministratorCitibank, N.A. AdvisorBlackRock Fund Advisors CustodianCitibank, N.A. DistributorBlackRock Investments, LLC Transfer AgentCitibank, N.A. TrusteeN/A Lead Market MakerLatour Trading Options OptionableOptionable Options Volume292 Put Options32 Call Options260 Short Interest259,952 shs Miscellaneous Outstanding Shares15,450,000Beta0.47 Creation Unit50,000 Creation Fee$306.00 The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report Top 10 IHE HoldingsEli Lilly and Company (NYSE:LLY)Holding Weight: 24.14%Johnson & Johnson (NYSE:JNJ)Holding Weight: 22.28%Pfizer (NYSE:PFE)Holding Weight: 4.65%Zoetis (NYSE:ZTS)Holding Weight: 4.63%Viatris (NASDAQ:VTRS)Holding Weight: 4.55%Merck & Co., Inc. (NYSE:MRK)Holding Weight: 4.48%Royalty Pharma (NASDAQ:RPRX)Holding Weight: 4.30%Bristol Myers Squibb (NYSE:BMY)Holding Weight: 4.29%Jazz Pharmaceuticals (NASDAQ:JAZZ)Holding Weight: 3.28%Corcept Therapeutics (NASDAQ:CORT)Holding Weight: 2.56%Full Holdings DetailsIHE Sector ExposureIHE Industry Exposure This page (NYSEARCA:IHE) was last updated on 10/16/2026 by MarketBeat.com Staff. From Our PartnersA new income category is drawing serious money - here's whyForbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the ...Investors Alley | SponsoredWhy Some AI Stocks Already Surged Over 300 PercentJason Bodner's system flagged Nvidia before a 7000 percent run, Super Micro Computer before a 2600 percent run...Brownstone Research | SponsoredTrump’s issues shocking Executive Order on U.S. DollarThree days into his second term, President Trump signed Executive Order 14178 a move the press barely covered....Banyan Hill Publishing | Sponsored$40,000,000,000,000The national debt just hit 40 trillion dollars, and the U.S. now spends more on interest payments than on its ...American Alternative | SponsoredUndiscovered Sub-$1 Gold-Silver Royalty Stock Takes FlightA small-cap gold and silver royalty company is generating record revenue from producing mines, yet shares stil...Digest Publishing | SponsoredMelting The GodsChina has slashed its U.S. Treasury holdings by more than 45% from their peak, while building gold vaults and ...Porter & Company | SponsoredFederal Reserve Reveals Disturbing New Plan To Control Your MoneyDocket No. OP-1670 is drawing attention for what it reveals about the Federal Reserve's next move. Buried on p...Weiss Ratings | SponsoredElon says the ‘S’ wordElon Musk and Sam Altman have sued each other and feuded for years. Yet within days of one another, both men d...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding iShares U.S. Pharmaceuticals ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share iShares U.S. Pharmaceuticals ETF With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IHE Stock Alerts